Subsequent Events	12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 13 — Subsequent Events The Company evaluated events subsequent to December 31, 2022 through March 2, 2023, the date the financial statements were issued. On January 3, 2023, TRACON Pharmaceuticals, Inc. prepaid its outstanding principal balance of $10.0 million on the senior secured loan. On January 4, 2023, the Company entered into an amendment (the "Credit Agreement Amendment") to the Amended and Restated Credit Agreement dated as of April 20, 2022 (the "Credit Agreement"), among the Company, as borrower; the financial institutions parties thereto as lenders (the "Lenders"); KeyBank National Association, as administrative agent for the Lenders; CIBC Bank USA, as documentation agent; MUFG Bank, Ltd., as co-documentation agent; and U.S. Bank Trust Company, National Association, as collateral custodian and paying agent. The Credit Agreement Amendment amended the Credit Agreement to, among other things, (i) revise the liquidity covenant to incorporate coverage for delayed draw term loans within the Company’s pledged loan portfolio and make additional clarifying modifications to the covenant; (ii) add a swingline sub-commitment within the KeyBank commitment to accommodate the potential for delayed fundings of Lender advances; and (iii) change the requirements for future facility amount increases under the accordion provisions of the Credit Agreement. In conjunction with the Credit Agreement Amendment, the Company increased the facility amount under the Credit Agreement by $50.0 million pursuant to the existing accordion provisions of the Credit Agreement. As part of the increased facility amount, Autobahn Funding Company LLC and Valley National Bank became new Lenders. The amendments to the Credit Agreement were effective as of January 4, 2023, with the exception of the revision to the liquidity covenant, which was effective as of December 31, 2022. On January 31, 2023, the Company funded an investment of $2.0 million to Intellisite Holdings, Inc. (dba Epic IO Technologies,Inc.). On February 23, 2023, the Board of Directors declared an ordinary distribution of $0.40 per share and a supplemental distribution of $0.05 per share for stockholders of record on March 7, 2023 payable on or before March 21, 2023. On February 23, 2023, the Company funded an investment of $4.0 million to Brivo, Inc.

Subsequent Events

12 Months Ended

Dec. 31, 2022

Note 13 — Subsequent Events

The Company evaluated events subsequent to December 31, 2022 through March 2, 2023, the date the financial statements were issued.

On January 3, 2023, TRACON Pharmaceuticals, Inc. prepaid its outstanding principal balance of $10.0 million on the senior secured loan.

On January 4, 2023, the Company entered into an amendment (the "Credit Agreement Amendment") to the Amended and Restated Credit Agreement dated as of April 20, 2022 (the "Credit Agreement"), among the Company, as borrower; the financial institutions parties thereto as lenders (the "Lenders"); KeyBank National Association, as administrative agent for the Lenders; CIBC Bank USA, as documentation agent; MUFG Bank, Ltd., as co-documentation agent; and U.S. Bank Trust Company, National Association, as collateral custodian and paying agent. The Credit Agreement Amendment amended the Credit Agreement to, among other things, (i) revise the liquidity covenant to incorporate coverage for delayed draw term loans within the Company’s pledged loan portfolio and make additional clarifying modifications to the covenant; (ii) add a swingline sub-commitment within the KeyBank commitment to accommodate the potential for delayed fundings of Lender advances; and (iii) change the requirements for future facility amount increases under the accordion provisions of the Credit Agreement. In conjunction with the Credit Agreement Amendment, the Company increased the facility amount under the Credit Agreement by $50.0 million pursuant to the existing accordion provisions of the Credit Agreement. As part of the increased facility amount, Autobahn Funding Company LLC and Valley National Bank became new Lenders. The amendments to the Credit Agreement were effective as of January 4, 2023, with the exception of the revision to the liquidity covenant, which was effective as of December 31, 2022.

On January 31, 2023, the Company funded an investment of $2.0 million to Intellisite Holdings, Inc. (dba Epic IO Technologies,Inc.).

On February 23, 2023, the Board of Directors declared an ordinary distribution of $0.40 per share and a supplemental distribution of $0.05 per share for stockholders of record on March 7, 2023 payable on or before March 21, 2023.

On February 23, 2023, the Company funded an investment of $4.0 million to Brivo, Inc.